55 results about "Proinflammatory cytokine" patented technology

The invention relates to the field of medicinal chemistry, and particularly discloses a piperidine derivative as well as a pharmaceutical composition, application and a preparation method thereof. The piperidine derivative has the following general formula. The piperidine derivative can be effectively used for treating or preventing multiple sclerosis, and shows an unexpected synergistic effect in an animal model: the piperidine derivative not only can significantly improve neurological function impairment and promote recovery, but also can deeply reduce the levels of key proinflammatory cytokines IFN-gamma and IL-17 at the same time. The invention provides a novel small molecule candidate drug with central permeability, neuroprotection and comprehensive immune regulation functions for treatment of multiple sclerosis.

The invention discloses an adipose-derived stem cell exosome compound loaded with silver nanoparticles and application of the adipose-derived stem cell exosome compound loaded with the silver nanoparticles, and ADSC-Exos loaded with the silver nanoparticles is developed by integrating AgNPs into an exosome of ADSCs. In vivo, the Exo-AgNPs can accelerate healing of infected wounds by reducing bacterial colonization and promoting collagen deposition, angiogenesis and M2 type macrophage polarization. In vitro, the Exo-AgNPs activates the functions of fibroblasts and vascular endothelial cells, and shows an excellent antibacterial property. In addition, the Exo-AgNPs induces polarization of M2 type macrophages and inhibits secretion of proinflammatory cytokines by activating autophagy. The results show that Exo-AgNPs is expected to become an ideal biological material for treating infected wounds.

Embodiments of the instant disclosure relate to intervention and / or treatment of autism spectrum disorder (ASD). Certain embodiments relate to treating a subject having ASD with one or more proinflammatory cytokines. In some embodiments, the one or more proinflammatory cytokines include, but are not limited to, granulocyte-macrophage colony-stimulating factor (GM-CSF) or derivative thereof, or fusion polypeptide thereof, or recombinant thereof. Other embodiments include a mouse model for assessing efficacy of treatment of ASD in humans and other mammals.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for relieving depression and clearing collaterals and a preparation, a pharmaceutical composition and application thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 6-12 parts of radix bupleuri, 9-15 parts of radix curcumae, 6-12 parts of rhizoma acori graminei, 3-9 parts of fructus gardeniae, 3-9 parts of polygala tenuifolia, 9-15 parts of radix paeoniae rubra and 9-20 parts of cortex albiziae. The traditional Chinese medicine composition provided by the invention can be used for remarkably improving depression-like behaviors of mice with depression, reversing synaptic injury and improving the expression of synaptic associated proteins SYP and PSD-95. The anti-depression mechanism of the traditional Chinese medicine composition is that the traditional Chinese medicine composition has the effects of synergistically inhibiting activation of microglial cells and reducing the level of proinflammatory cytokines such as Tnf alpha, Il1beta and Il6, so that neuroinflammation is remarkably inhibited, and the traditional Chinese medicine composition has the advantages of novel formula, definite mechanism and definite curative effect for treating depression, particularly patients with anxiety and dysphoria symptoms.

The present application relates to the technical field of biological medicine engineering, and provides application of RBFOX2 inhibitor in treatment of inflammatory bowel disease, and particularly relates to the role of interfering RNA or antisense oligonucleotide or recombinant expression vector targeting RBFOX2 coding sequence in preparation of products for treating colitis and its related symptoms and / or other complications, and also relates to corresponding recombinant vectors or pharmaceutical compositions. The RBFOX2 inhibitor can effectively reduce the level of proinflammatory cytokines, inhibit the activation of macrophages, has effective application value in relieving and treating colonic inflammation and other symptoms and / or other complications of inflammatory bowel disease, provides a new target for treatment of inflammatory bowel disease, and has wide clinical application prospect.

This invention proposes an anti-CD3 antibody or its antigen-binding fragment and its applications. It comprises: heavy chain variable region CDRs and light chain variable region CDRs; wherein the heavy chain variable region CDRs have an amino acid sequence as shown in any one of SEQ ID NO: 1-3, 7-8, and 74-86 or a conserved modified form thereof; and / or the light chain variable region CDRs have an amino acid sequence as shown in any one of SEQ ID NO: 4-6, 9, and 87-92 or a conserved modified form thereof. The anti-CD3 antibody or its antigen-binding fragment of this invention can bind to human CD3 protein and can reduce the production of pro-inflammatory cytokines. Bispecific antibodies constructed using this antibody exhibit high PBMC-based tumor-killing activity and weak pro-inflammatory cytokine secretion-promoting properties. Therefore, pharmaceutical compositions prepared using this anti-CD3 antibody or its antigen-binding fragment or its multispecific antibody have better safety and high clinical application and drug development value.

This invention discloses a novel use of carvedilol or its salts and compositions, as well as the composition and its preparation method. The β-blocker or pharmaceutical composition provided by this invention has good efficacy in preventing, treating, and / or alleviating drug-induced liver injury, effectively reducing mortality caused by this disease; simultaneously, it can significantly reduce serum transaminase levels, alleviate symptoms such as liver and spleen edema, and has a good inhibitory effect on pro-inflammatory cytokines. Furthermore, experimental results further indicate that the combination of the β-blocker and pharmaceutically acceptable excipients (steviosides and / or glycyrrhizate) has good safety and is easily dissolved, released, and / or absorbed, improving the bioavailability of carvedilol and exhibiting a synergistic effect, showing promising application prospects.

The application discloses a kind of composite microbial fermentation inoculant and its application in metagenomic food preparation with multi-grain as substrate, belong to the field of microbial fermentation technology.The application adds composite microbial fermentation inoculant into multi-grain substrate containing longan meat extract to obtain metagenomic food with multi-grain as substrate.The metagenomic food with multi-grain as substrate is used for animal experiment, and the blood pressure reduction rate of complex group is higher, the fasting blood glucose value and the area under curve are lower, the body weight and TC value are smaller, the proinflammatory cytokines IL-1β, IL-6 and TNF-α are smaller, and the chao and ace index are larger.It is shown that compared with the use of composite microbial fermentation inoculant, longan meat extract or multi-grain substrate alone, the metagenomic food with multi-grain as substrate obtained by the application has good effects of reducing blood pressure, reducing blood sugar and reducing blood lipid, can reduce inflammatory response, remove body toxins and regulate intestinal function.

The invention relates to a skin injury organ model and a method for screening drugs by using the skin injury organ model, and the skin injury organ model is characterized in that skin cells, accessory structures, nerve cells, fat cells and the like form structures similar to actual skin by using an air-liquid interface skin organ preparation technology; and the damaged skin is prepared by irradiating the skin-like organ with ultraviolet rays which actually reach the ground surface. In the present invention, the skin barrier is damaged and the activity of a matrix proteolytic enzyme is improved to promote the decomposition of collagen while increasing the secretion of pro-inflammatory cytokines by irradiating with solar-simulated ultraviolet light comprising 94.5% ultraviolet light (UV-A) and 5.5% ultraviolet light (UV-B), thereby well simulating the characteristics of skin injury caused by ultraviolet light. Therefore, the invention can be used as a model of skin injury and photoaging caused by ultraviolet rays, and can be useful in potential therapeutic drug screening.

The application discloses a blood purification membrane for removing proinflammatory cytokines and a preparation method thereof. The method comprises the following steps: dissolving a film-forming material and an additive in a solvent to obtain a homogeneous casting solution; preparing a hollow fiber plasma separation membrane by using a non-solvent phase inversion method; and constructing a proinflammatory cytokine adsorption functional layer on the outer surface of the hollow fiber plasma separation membrane to obtain a homogeneous blood purification membrane. The blood purification membrane prepared by the method has the plasma separation function, can separate inflammatory cytokines from the inner side of the membrane to the outer side of the membrane, and has excellent blood compatibility on the inner surface of the membrane and the adsorption and removal function of pathogenic toxins and proinflammatory cytokines on the outer surface of the membrane. In the construction process, the two functions do not interfere with each other, the blood compatibility of the material is improved, the removal rate of the pathogenic toxins is not affected, and the problem of the reduction of the toxin adsorption and removal effect caused by the existing technology for improving the blood compatibility of the plasma perfusion adsorption resin is solved.

The invention discloses application of ethyl sulfate in preparation of a medicine for preventing and / or treating inflammatory bowel diseases, and belongs to the technical field of medicines. The invention finds that ethyl sulfate has the effect of preventing and / or treating inflammatory bowel disease for the first time: the ethyl sulfate can obviously improve the survival index of an inflammatory bowel disease model mouse and reduce the disease activity index; the symptoms of weight loss, stool character, inflammation-related diarrhea and bloody stool are relieved; the length of colon tissue is improved, and the size and number of tumors in colorectum are reduced; the pharmaceutical composition has the effects of inhibiting the level of proinflammatory cytokines (TNF-alpha, IL-8, IL-1beta and IL-6), recovering the level of anti-inflammatory cytokines (IL-10 and INF-gamma), inhibiting the enzymatic activity of MPO and MDA and improving the enzymatic activity of SOD and GSH-Px, so that the inflammatory reaction and oxidative stress reaction in the inflammatory bowel disease microenvironment are improved, and the pharmaceutical composition has the pharmacological action of preventing and / or treating the inflammatory bowel disease.

The invention relates to an application of bacillus subtilis ST-1086. After the bacillus subtilis ST-1086, the postbiotics or the composition containing the bacillus subtilis ST-1086 and the postbiotics are co-cultured with macrophage RAW264.7 cells, the secretion amount of proinflammatory cytokines TNF-alpha, IL-6 and IL-1beta of the RAW264.7 cells and the secretion amount of anti-inflammatory cytokines IL-10 of the RAW264.7 cells can be increased, the immune enhancement effect is achieved by regulating and controlling the network balance of the cytokines, and then the effect of improving the immunity is achieved. The bacillus subtilis ST-1086 is classified and named as bacillus subtilis, and the preservation number of the bacillus subtilis ST-1086 is CGMCC (China General Microbiological Culture Collection Center) No. 17895.

The invention discloses lactobacillus helveticus capable of relieving rheumatoid arthritis and application of the lactobacillus helveticus, and belongs to the technical field of microorganisms. A strain of lactobacillus helveticus CCFM1501 is screened out, the lactobacillus helveticus CCFM1501 can produce cell wall protease, amino-peptidase and aromatic transaminase at high yield, and has the effect of relieving rheumatoid arthritis, and the specific effects are that the thickness of a posterior claw of a rat with rheumatoid arthritis is reduced, and knee joint injury is improved; the content of proinflammatory cytokines in the serum of rheumatoid arthritis rats is reduced, the content of anti-inflammatory cytokines IL-10 in the serum of the rheumatoid arthritis rats is increased, the content of arthritis specific antibodies in the serum of the rheumatoid arthritis rats is reduced, the mRNA relative expression quantity of colonic tight junction proteins ZO-1 and Occludin in the rheumatoid arthritis rats is increased, and the anti-inflammatory activity of the rheumatoid arthritis rats is improved. The content of acetic acid and butyric acid in excrement of rats with rheumatoid arthritis is increased.

The invention discloses a green extraction method of quercetin from kitchen waste pericarp and application thereof, and relates to the technical field of green extraction of natural products, the green extraction method comprises the following steps: S1, a pericarp pretreatment step; s2, preparing an extracting solution; s3, an extraction step; s4, a solid-liquid separation step; s5, an enrichment and purification step; according to the method disclosed by the invention, the dissolution efficiency and selectivity of the quercetin from the pericarp matrix are remarkably improved through the synergistic effect of enzymatic degradation and the deep eutectic solvent (DES) and assisted by physical energy, so that the recovery rate and the enrichment purity of the target component are improved, the subsequent purification burden is relieved, and the practical value of the extract is enhanced. The quercetin enrichment preparation can obviously inhibit the activation of an NF-kappa B signal channel and reduce the expression of downstream proinflammatory cytokines under a non-lethal administration concentration, so that the quercetin enrichment preparation shows the effects of reducing the activation of microglial cells and inhibiting neuroinflammatory response in an in-vitro cell model and an animal neuroinflammatory model; the pathological process related to neuroinflammation can be relieved or prevented.

The invention provides a ganoderma lucidum molecular ecological liquid extract obtained through specific fermentation and a preparation method and application thereof, and belongs to the technical field of microbial fermentation. According to the method, an improved fermentation culture medium is adopted, 5-8% of CO2 is introduced, fermentation is performed for 90-180 days at the temperature of 30-32 DEG C under the condition that the concentration of dissolved oxygen in the environment is kept to be 20-30%, and after purification, the extract of the ganoderma lucidum molecular ecological liquid is obtained. According to the myxomycete molecular ecological liquid prepared by the preparation method provided by the invention, the content of active ingredients for relieving the symptoms of the chronic obstructive pulmonary disease can be remarkably increased; moreover, an in-vitro cell experiment verifies that the extract of the ganoderma lucidum molecular ecological liquid has an inhibition effect on an A549 cell line, and an animal experiment further proves that the extract of the ecological liquid can regulate and control the expression level of proinflammatory cytokines, so that lung inflammation is inhibited, pathological injury of lung tissues is relieved, and local abnormal conditions of the lung are improved.

The present disclosure relates to methods of manufacturing Chimeric Antigen Receptor (CAR) T cells. Notably, the manufacturing method omits the CD14+ / CD25+ depletion step. Additionally, by starting with CD62L enrichment of naïve and memory T cells, the resulting CAT T cells show reduced release of proinflammatory cytokines. Furthermore, the transduced cells show improved quiescence after removal of the transactivation agent.

The application discloses application of CPI2 protein in preparation of anti-gouty arthritis drugs and belongs to the technical field of biological medicine. The application discloses the application of the CPI2 protein in preparation of anti-gouty arthritis drugs, and the amino acid sequence of the CPI2 protein is shown as SEQ ID NO. 1. The CPI2 protein disclosed by the application can reduce joint swelling caused by sodium urate, reduce inflammatory cell infiltration, reduce the levels of proinflammatory cytokines IL-1beta, IL-6 and TNF-alpha, increase the level of anti-inflammatory cytokine IL-10, increase the activities of SOD and GSH-Px, and reduce the content of MDA, and can be prepared as a drug for preventing or treating gouty arthritis and has clinical application value.

The application relates to a kind of macrolide polymers and its preparation method and the application of inhibiting the effect of proinflammatory cytokines, and is related to the field of polymer chemistry and biomedical technology, specifically to the application of a kind of macrolide derivative shown in formula (I) in the preparation of proinflammatory cytokine effect inhibitor drugs, which has the potential to be developed as a new type of inflammation factor activity inhibitor drug.

The present disclosure generally relates to probiotics for reducing the release of proinflammatory cytokines. In particular, the present disclosure provides a composition comprising Lacticaseibacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis that can reduce the overall pro-inflammatory cytokines in a subject such as, for example, interleukin-6 (IL-6). The present disclosure provides a method of preventing, reducing, or ameliorating the symptoms of stress and / or anxiety, in a subject in need thereof, with a composition comprising Lacticaseibacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis.

The invention discloses bifidobacterium longum CCFM1508 capable of activating a TFEB-HKDC1 autophagy pathway and application of the bifidobacterium longum CCFM1508 in the aspect of colon aging resistance, and belongs to the field of microorganisms. The bifidobacterium longum CCFM1508 provided by the invention has an autophagy regulation capability and can be used for effectively improving colon aging. Through intervention of the bifidobacterium longum CCFM1508, damage to colon tissue of an aged mouse can be remarkably relieved, activity of aging-related beta-galactosidase is inhibited, cell apoptosis is regulated, the level of proinflammatory cytokines is inhibited, oxidative damage degree in the colon tissue is slowed down, transcriptional levels of aging markers p21 and p53 in the colon tissue are remarkably reduced, an autophagy pathway of TFEB-HKDC1 can be activated, and the anti-aging effect is achieved. The autophagy level of the colon tissue is adjusted, and the colon aging resisting effect is achieved. Therefore, the application range of the bifidobacterium longum as probiotics is expanded, and the bifidobacterium longum has a huge application prospect in relieving colon aging.

The invention discloses an application of green tendon relaxing ketone in preparation of a medicine for treating rheumatoid diseases. The invention proposes and verifies that the green tendon relaxing ketone can effectively promote fibroblast-like synovial cell ferroptosis so as to inhibit synovial hyperplasia and inhibit the expression of proinflammatory cytokines so as to effectively relieve the progress of rheumatoid arthritis for the first time, and has an excellent application prospect in clinical treatment of rheumatoid diseases.

The invention belongs to the technical field of biological medicine, and particularly relates to application of pseudo-ginseng carbon quantum dots in preparation of a medicine for treating renal ischemia-reperfusion injury, the carbon quantum dots are synthesized by taking pseudo-ginseng as a raw material through a hydrothermal method, and the pseudo-ginseng carbon quantum dots have the antioxidant enzyme activity property, can effectively relieve cell oxidative stress and inhibit secretion of proinflammatory cytokines, and can be used for preparing a medicine for treating renal ischemia-reperfusion injury. The pseudo-ginseng carbon quantum dots specifically gather in the damaged kidney, so that the renal ischemia reperfusion injury of the mouse is obviously relieved; the pseudo-ginseng carbon quantum dots can relieve kidney injury through the following ways: reducing abundance of escherichia coli-shigella, reducing the level of indol sulfate in the kidney, regulating tryptophan-indole metabolism, regulating an AHR-Raf-ERK signal channel, down-regulating the levels of TNF-alpha and malonaldehyde, and regulating the level of glutathione. A catalytic mechanism and a multi-omics regulatory pathway of the pseudo-ginseng carbon quantum dots in renal ischemia reperfusion injury are disclosed, and experimental evidence is provided for'intestinal tract-kidney axis' in kidney disease treatment.

The invention discloses an application of Anti-TSLP (Transcriptional Stem Like Protein) in prevention or treatment of abdominal aortic aneurysm. The Anti-TSLP is an anti-TSLP (Transcriptional Stem Like Protein) monoclonal antibody. The application of Anti-TSLP as a monoclonal antibody drug in prevention or treatment of abdominal aortic aneurysm is found for the first time. By intraperitoneal injection of Anti-TSLP and neutralization of TSLP pro-inflammatory cytokines, macrophage M1 / M2 phenotype can be effectively regulated, macrophage-mediated inflammatory response can be regulated and controlled, abdominal aortic aneurysm can be relieved, and a potential treatment scheme is provided for precise treatment of patients with clinical abdominal aortic aneurysm.

The present technology relates to an implantable or bio-wearable cytokine sensor that is configured to continuously detect in vivo mRNA and / or polypeptide levels of proinflammatory cytokines (e.g. interleukin-6, IFNy, IL-1, IL-10, TNFα, etc.) and methods of using the same to monitor adverse CAR-T-related toxicity in cancer patients.

The application relates to the field of biological medicine, and discloses a molecular glue compound targeting a PHB1-PHB2 heterodimer interface and application thereof. The application first identifies a druggable shallow groove pocket located at the PHB1-PHB2 heterodimer interface, and screens out a molecular glue compound represented by N-(pyridin-4-ylmethyl)-3-(1-methyl-1H-indol-3-yl)propanamide. The compound can stabilize a PHB1-PHB2 heterodimer complex, significantly inhibit LPS-induced proinflammatory cytokine release and lung infiltration of neutrophils, reduce pathological damage of lung tissue, and significantly improve the survival rate of a mouse acute lung injury model, and thus is expected to be used for preventing and / or treating acute lung injury.

The invention relates to a specific small molecule compound of a GLYR1 target spot and application thereof, and belongs to the field of biological medicine. The invention provides a small molecule compound C20H32O5, which is specifically combined with 27185-285amino acid motifs of glyoxylate reductase homologue-1 (GLYR1) protein, so that the combining capacity of the GLYR1 and chromosome DNA in a cell nucleus is reduced, and gene transcription is inhibited; meanwhile, the retention of GLYR1 in cytoplasm is prolonged, and the phosphorylation levels of ERK and MAPK are reduced, so that the transcription up-regulation of proinflammatory cytokines in macrophages is inhibited. The compound rapidly inhibits inflammatory storm caused by coronavirus infection, and significantly reduces severe illness and death risks; experiments prove that the survival rate in an SARS-CoV-2 infected mouse model is increased to 100% from 63.5%, the survival rate in an MHV-3 infected model is remarkably increased, and tissue pathological injuries of lungs and spleens are relieved.

Disclosed are a composition for preventing and / or treating cytokine release syndrome and a method of preventing and / or treating cytokine release syndrome. The composition includes an arylethylene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof as an active ingredient. The method includes administering an effective amount of the arylethylene compound, an isomer thereof, a pharmaceutically acceptable salt thereof, or a solvate thereof to a subject in need. The cytokine release syndrome can be caused by a toxic infection. The administration of the compound reduces the level of proinflammatory cytokines in the subject.

The invention discloses an application of total glucosides of paeony in treatment of psoriasis in combination with Jikukiespecially and calcipotriol, and relates to the technical field of medical treatment, a psoriasis-like mouse model induced by imiquimod is established, and the synergistic treatment effect of a triple therapy of total glucosides of paeony, Jikukiespecially and calcipotriol is verified; the application comprises the step of jointly applying the three medicines according to a specific dosage. The triple therapy can improve erythema, scale and infiltration symptoms of psoriasis-like skin lesion, effectively reduce the area and severity index score of psoriasis, and inhibit the protein and mRNA expression level of key proinflammatory cytokines in skin lesion tissues; compared with a single drug or a combination of two drugs, the triple therapy provided by the invention shows a better treatment effect, and a new and effective drug combination scheme is provided for clinical treatment of psoriasis.

The invention relates to the technical field of medicine, in particular to application of a compound in treatment of psoriasis, the compound is an AMPK activator Aldometanib, and the chemical structural formula of the compound is as shown in Figure 1. The research result shows that the Aldometanib can effectively relieve the psoriasis-like phenotype of mice, the erythema of the mice is converted from bright red to light red, the area is reduced, silver-white scales attached to the skin surface are thinned, and the psoriasis area and severity index (PASI) score is remarkably reduced. The mouse back skin lesion tissue is subjected to HE dyeing, the visible epidermis thickness is recovered to be close to the normal level through microscopic observation, inflammatory cell infiltration lesions on the superficial layer of dermis and around blood vessels are reduced, and the number is remarkably reduced. A mouse serum ELISA detection result shows that the expression of pro-inflammatory cytokines TNF alpha, IL-1beta and IL-6 is reduced. The Aldometanib disclosed by the invention is remarkable in anti-psoriasis effect, safe and non-toxic, and is expected to become a novel therapeutic drug for psoriasis.

The invention discloses an application of a compound medicine in preparation of an anti-new coronavirus medicine, relates to the technical field of medicines, and comprises the following applications: an application of hemp seed oil and curcuma zedoary volatile oil in preparation of the anti-new coronavirus medicine; preparing a medicine for preventing, relieving or treating new coronavirus infection; preparing a medicine for inhibiting proinflammatory cytokines caused by the new coronavirus; the invention relates to inhibition of novel coronavirus for non-therapeutic and diagnostic purposes. The traditional Chinese medicine composition has a prominent anti-inflammatory effect on inflammation caused by new coronavirus infection, can effectively improve the level of inflammatory factors within 3 days, directly relieves the inflammation caused by new coronavirus infection, and is stable in medicine effect. The traditional Chinese medicine composition has the effects of resisting oxidation, improving digestion, resisting viruses and the like, comprehensively improves symptoms and does not have obvious toxic or side effects.